Cargando…

Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis

BACKGROUND: HIV(+) kidney transplant (KT) for persons living with HIV (PLWH) is both safe and effective, with comparable patient and graft survival rates relative to HIV(-) KT. The objective of this study was to evaluate the cost-effectiveness of HIV(+) KT relative to HIV(-) KT and dialysis. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Joe, Winston B, Eaton, Ellen F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631178/
http://dx.doi.org/10.1093/ofid/ofx163.1103
_version_ 1783269386823401472
author Joe, Winston B
Eaton, Ellen F
author_facet Joe, Winston B
Eaton, Ellen F
author_sort Joe, Winston B
collection PubMed
description BACKGROUND: HIV(+) kidney transplant (KT) for persons living with HIV (PLWH) is both safe and effective, with comparable patient and graft survival rates relative to HIV(-) KT. The objective of this study was to evaluate the cost-effectiveness of HIV(+) KT relative to HIV(-) KT and dialysis. METHODS: A decision-tree framework was used to assess the cost-effectiveness of the above treatment options for PLWH. Clinical outcomes at 3 years for KT and effectiveness data (expressed in QALYs) were abstracted from previous publications, when available. Costs were assigned from a payer’s perspective using the US Renal Data System and published literature (expressed in 2014 USD). This analysis assumed a three-year time horizon. Sensitivity analyses were explored to understand how changes in 1) acute KT rejection and 2) KT failure impact cost effectiveness. Limitations include small sample size and short follow up time in referenced studies and a lack of health utility data in HIV positive persons with renal failure. We used TreeAge Software (Williamstown, MA). RESULTS: HIV(+) KT was most cost effective ($299,904/QALY) while both HIV(-) KT ($329,676) and dialysis ($444,645) were dominated, meaning more costly and less effective. Results were sensitive to the higher KT failure (26% vs. 16%) and acute rejection (39% vs. 17%) observed with HIV(-) KT relative to HIV(+) KT. In sensitivity analysis, as HIV(+) KT rejection rates approach 20%, HIV(-) KT becomes a cost-effective option. As HIV(+) KT failure rates approach 26%, HIV(-) KT becomes cost effective. CONCLUSION: Despite its limitations, this analysis demonstrates that HIV(+) kidney transplantation is a cost-effective alternative for PLWH under certain conditions. As KT outcomes, like graft failure and acute rejection rates, continue to improve, it is likely that both HIV positive and negative KT will be cost-effective alternatives to dialysis. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631178
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56311782017-11-07 Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis Joe, Winston B Eaton, Ellen F Open Forum Infect Dis Abstracts BACKGROUND: HIV(+) kidney transplant (KT) for persons living with HIV (PLWH) is both safe and effective, with comparable patient and graft survival rates relative to HIV(-) KT. The objective of this study was to evaluate the cost-effectiveness of HIV(+) KT relative to HIV(-) KT and dialysis. METHODS: A decision-tree framework was used to assess the cost-effectiveness of the above treatment options for PLWH. Clinical outcomes at 3 years for KT and effectiveness data (expressed in QALYs) were abstracted from previous publications, when available. Costs were assigned from a payer’s perspective using the US Renal Data System and published literature (expressed in 2014 USD). This analysis assumed a three-year time horizon. Sensitivity analyses were explored to understand how changes in 1) acute KT rejection and 2) KT failure impact cost effectiveness. Limitations include small sample size and short follow up time in referenced studies and a lack of health utility data in HIV positive persons with renal failure. We used TreeAge Software (Williamstown, MA). RESULTS: HIV(+) KT was most cost effective ($299,904/QALY) while both HIV(-) KT ($329,676) and dialysis ($444,645) were dominated, meaning more costly and less effective. Results were sensitive to the higher KT failure (26% vs. 16%) and acute rejection (39% vs. 17%) observed with HIV(-) KT relative to HIV(+) KT. In sensitivity analysis, as HIV(+) KT rejection rates approach 20%, HIV(-) KT becomes a cost-effective option. As HIV(+) KT failure rates approach 26%, HIV(-) KT becomes cost effective. CONCLUSION: Despite its limitations, this analysis demonstrates that HIV(+) kidney transplantation is a cost-effective alternative for PLWH under certain conditions. As KT outcomes, like graft failure and acute rejection rates, continue to improve, it is likely that both HIV positive and negative KT will be cost-effective alternatives to dialysis. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631178/ http://dx.doi.org/10.1093/ofid/ofx163.1103 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Joe, Winston B
Eaton, Ellen F
Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
title Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
title_full Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
title_fullStr Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
title_full_unstemmed Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
title_short Management of End Stage Renal Disease in Persons Living with HIV: A Cost-Effectiveness Analysis
title_sort management of end stage renal disease in persons living with hiv: a cost-effectiveness analysis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631178/
http://dx.doi.org/10.1093/ofid/ofx163.1103
work_keys_str_mv AT joewinstonb managementofendstagerenaldiseaseinpersonslivingwithhivacosteffectivenessanalysis
AT eatonellenf managementofendstagerenaldiseaseinpersonslivingwithhivacosteffectivenessanalysis